HK1248311B - 預測死亡率及檢測重症疾病 - Google Patents

預測死亡率及檢測重症疾病

Info

Publication number
HK1248311B
HK1248311B HK18107615.0A HK18107615A HK1248311B HK 1248311 B HK1248311 B HK 1248311B HK 18107615 A HK18107615 A HK 18107615A HK 1248311 B HK1248311 B HK 1248311B
Authority
HK
Hong Kong
Prior art keywords
severe disease
predicting mortality
detecting severe
mortality
hospital
Prior art date
Application number
HK18107615.0A
Other languages
English (en)
Inventor
James V Snider
Sven Jacobson
Original Assignee
Critical Care Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Critical Care Diagnostics Inc filed Critical Critical Care Diagnostics Inc
Publication of HK1248311B publication Critical patent/HK1248311B/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
    • G16Z99/00—Subject matter not provided for in other main groups of this subclass
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Rehabilitation Therapy (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
HK18107615.0A 2006-04-24 2015-09-17 預測死亡率及檢測重症疾病 HK1248311B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79435406P 2006-04-24 2006-04-24
US80036206P 2006-05-15 2006-05-15
US90460807P 2007-03-02 2007-03-02

Publications (1)

Publication Number Publication Date
HK1248311B true HK1248311B (zh) 2020-03-20

Family

ID=38656334

Family Applications (3)

Application Number Title Priority Date Filing Date
HK12104804.4A HK1164443A1 (zh) 2006-04-24 2012-05-16 預測死亡率及檢測重症疾病
HK15109122.5A HK1208724A1 (zh) 2006-04-24 2015-09-17 基於 水平評估受試者所獲治療之效力
HK18107615.0A HK1248311B (zh) 2006-04-24 2015-09-17 預測死亡率及檢測重症疾病

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HK12104804.4A HK1164443A1 (zh) 2006-04-24 2012-05-16 預測死亡率及檢測重症疾病
HK15109122.5A HK1208724A1 (zh) 2006-04-24 2015-09-17 基於 水平評估受試者所獲治療之效力

Country Status (12)

Country Link
US (7) US7998683B2 (zh)
EP (5) EP2848938B1 (zh)
JP (4) JP5383480B2 (zh)
AT (2) ATE476657T1 (zh)
AU (1) AU2007244927B2 (zh)
CA (1) CA2650201C (zh)
DE (1) DE602007008224D1 (zh)
DK (3) DK2848938T3 (zh)
ES (4) ES2646142T3 (zh)
HK (3) HK1164443A1 (zh)
PL (2) PL2386860T4 (zh)
WO (1) WO2007127749A2 (zh)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038794A2 (en) 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
PT3072978T (pt) 2002-05-09 2018-10-15 Brigham & Womens Hospital Inc 1l1rl-1 como um marcador de doença cardiovascular
EP1731910A1 (en) * 2005-06-07 2006-12-13 F. Hoffmann-La Roche Ag Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases
ES2646142T3 (es) 2006-04-24 2017-12-12 Critical Care Diagnostics, Inc. Evaluación de la eficacia de un tratamiento en un sujeto en función de los niveles de ST2
WO2007143295A2 (en) * 2006-04-27 2007-12-13 Critical Care Diagnostics, Inc. Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
DK2021796T3 (da) 2006-05-01 2012-05-29 Critical Care Diagnostics Inc Diagnose af hjerte-kar-sygdom
DK2019965T3 (en) * 2006-05-02 2015-07-20 Critical Care Diagnostics Inc DIFFERENTIAL BETWEEN LUNG AND Cardiovascular Disease
AU2007267561B2 (en) * 2006-05-25 2012-05-17 Momenta Pharmaceuticals, Inc. Low molecular weight heparin composition and uses thereof
US11389080B2 (en) 2007-11-28 2022-07-19 Intervet Inc. System and method for diagnosis of bovine diseases using auscultation analysis
WO2009100907A1 (en) * 2008-02-14 2009-08-20 Dianeering Diagnostics Engineering And Research Gmbh Means and methods for assessing the risk of patients presenting to emergency departments based on very low concentrations of troponin i or t or using a combination of markers
EP2242494A4 (en) * 2008-02-20 2013-01-02 Momenta Pharmaceuticals Inc METHODS OF MANUFACTURING LOW MOLECULAR WEIGHT OF HEPARIN COMPOSITIONS
SI2827152T1 (sl) * 2008-04-18 2016-10-28 Critical Care Diagnostics,Inc. Napovedovanje tveganja večjih neželenih srčno-žilnih dogodkov
EP2141499A1 (en) * 2008-07-02 2010-01-06 Apoptec AG COPD diagnosis
US20100099958A1 (en) * 2008-10-16 2010-04-22 Fresenius Medical Care Holdings Inc. Method of identifying when a patient undergoing hemodialysis is at increased risk of death
US9883799B2 (en) * 2008-10-16 2018-02-06 Fresenius Medical Care Holdings, Inc. Method of identifying when a patient undergoing hemodialysis is at increased risk of death
US10064580B2 (en) 2008-11-07 2018-09-04 Intervet Inc. System and method for determining antibiotic effectiveness in respiratory diseased animals using auscultation analysis
JP2012063140A (ja) * 2008-12-15 2012-03-29 Hokkaido Univ 糖鎖分析による肺がんの診断方法
JP2012063139A (ja) * 2008-12-15 2012-03-29 Hokkaido Univ 糖鎖分析による膵臓がんの診断方法
WO2011038047A1 (en) * 2009-09-23 2011-03-31 Momenta Pharmaceuticals, Inc. Methods of treatment with a low molecular weight heparin composition
BR112012011230A2 (pt) * 2009-11-13 2016-04-05 Bg Medicine Inc fatores de risco e previsão de infarto do miocárdio
AU2011231537B2 (en) * 2010-03-26 2016-05-12 Mycartis Nv LTBP2 as a biomarker for renal dysfunction, glomerular filtration rate, dyspnea, acute heart failure, left ventricular hypertrophy, cardiac fibrosis, preeclampsia, pregnancy-associated proteinuria
RU2625014C2 (ru) 2010-04-09 2017-07-11 Критикал Кэа Дайэгностикс, Инк. Антитела против растворимого st-2 человека и способы анализа
JP2011232164A (ja) * 2010-04-27 2011-11-17 Keio Gijuku 肝臓疾患マーカー、その測定方法、装置及び医薬品の検定方法
US20110295613A1 (en) * 2010-05-28 2011-12-01 Martin Coyne Inpatient utilization management system and method
RU2618437C2 (ru) * 2010-11-01 2017-05-03 Б.Р.А.Х.М.С Гмбх Оценка прогноза и риска пациентов с неспецифическими жалобами
GB201021289D0 (en) * 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
EP2646823B9 (en) 2010-12-02 2017-02-22 Fresenius Medical Care Holdings, Inc. Method of identifying when a patient undergoing hemodialysis is at increased risk of death
US8728742B2 (en) 2011-03-17 2014-05-20 Critical Care Diagnostics, Inc. Methods predicting risk of an adverse clinical outcome
JP6134316B2 (ja) 2011-07-18 2017-05-24 クリティカル ケア ダイアグノスティクス インコーポレイテッド 心臓血管疾患を治療する方法および運動療法の有効性を予測する方法
US20130157290A1 (en) * 2011-12-16 2013-06-20 Yves Levy Soluble st2 as a marker for disease
EP3434260A1 (en) * 2012-05-18 2019-01-30 Critical Care Diagnostics, Inc. Methods for treating or predicting risk of ventricular tachyarrhythmia event
JO3623B1 (ar) 2012-05-18 2020-08-27 Amgen Inc البروتينات المرتبطة بمولد المستضاد st2
RU2019107598A (ru) 2012-08-16 2019-03-28 Критикал Кэа Дайэгностикс, Инк. Способы прогнозирования риска развития гипертензии
RU2015110054A (ru) * 2012-08-21 2016-10-10 Критикал Кэа Дайэгностикс, Инк. Мультимаркерная стратификация риска
MX362388B (es) 2013-02-06 2019-01-15 Geissler Companies Llc Sistema y metodo para determinar la efectividad antibiotica en animales con enfermedades del sistema respiratorio usando un analisis de auscultacion.
CN106461636A (zh) 2014-01-10 2017-02-22 重症监护诊断股份有限公司 用于测定心力衰竭风险的方法和系统
US10670611B2 (en) 2014-09-26 2020-06-02 Somalogic, Inc. Cardiovascular risk event prediction and uses thereof
EP3213085B2 (en) 2014-10-29 2022-09-28 Roche Diagnostics GmbH Biomarkers for risk prediction of progression of chronic heart failure and mortality
EA201791029A1 (ru) 2014-11-10 2017-12-29 Дженентек, Инк. Антитела против интерлейкина-33 и их применение
CN107109494B (zh) 2014-11-10 2023-10-27 豪夫迈·罗氏有限公司 Il-33介导型疾病的治疗方法和诊断方法
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
CN106952043B (zh) * 2017-03-23 2021-04-13 国家电网公司客户服务中心 一种计划停电敏感度评估方法和装置
CN108982871B (zh) * 2018-07-19 2021-09-24 北京市心肺血管疾病研究所 血清sST2在小儿扩张型心肌病预后中的应用
IL296256A (en) 2020-03-13 2022-11-01 Genentech Inc Antibodies against interleukin-33 and uses thereof
WO2023201054A1 (en) * 2022-04-15 2023-10-19 Memorial Sloan-Kettering Cancer Center Multi-modal machine learning to determine risk stratification

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) * 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
US5206140A (en) * 1988-06-24 1993-04-27 Research Corporation Technologies, Inc. Assay for soluble crosslinked fibrin polymers
JPH0731479Y2 (ja) 1989-06-02 1995-07-19 内橋エステック株式会社 温度ヒューズ
US5217899A (en) 1990-08-24 1993-06-08 The General Hospital Corporation Cell stretching apparatus
JP2665850B2 (ja) 1991-11-14 1997-10-22 塩野義製薬株式会社 ｈＢＮＰのＣ端を認識するモノクロ−ナル抗体
GB9211686D0 (en) * 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
JPH0731479A (ja) 1993-02-23 1995-02-03 Shinichi Tominaga マウスｓｔ２ｌをコードするｄｎａ、該ｄｎａの発現産物、該ｄｎａを発現させることによる発現産物の製造方法
US6066322A (en) * 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
WO1998007754A1 (en) 1996-08-23 1998-02-26 Human Genome Sciences, Inc. T1 receptor-like ligand ii
EP0981619A1 (en) 1997-02-28 2000-03-01 Human Genome Sciences, Inc. T1/st2-receptor ligand iii
DE19711932A1 (de) 1997-03-21 1998-09-24 Anne Katrin Dr Werenskiold In vitro-Verfahren zum Prognostizieren des Krankheitsverlaufs von Patienten mit Mammakarzinom und/oder zum Diagnostizieren eines Mammakarzinoms
PT1493439E (pt) * 1997-04-02 2012-01-10 Brigham & Womens Hospital Meio de avaliação do perfil de risco de um indivíduo para uma doença aterosclerótica
ATE489633T1 (de) * 1997-06-10 2010-12-15 Lpath Inc Verfahren zum frühzeitigen nachweis herzerkrankungen
JP3516655B2 (ja) 1997-09-11 2004-04-05 塩野義製薬株式会社 Ｂｎｐの免疫測定法
GB9727172D0 (en) 1997-12-24 1998-02-25 Univ Glasgow Reagents specific for st2l and uses therefor
GB9827348D0 (en) 1998-12-12 1999-02-03 Univ Leicester Natriuretic peptide
AU2055300A (en) 1998-12-18 2000-07-03 Scios Inc. Methods for detection and use of differentially expressed genes in disease states
AU5309600A (en) 1999-06-02 2000-12-18 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of immune disorders
FR2795823B1 (fr) 1999-07-01 2001-11-23 Inst Nat Sante Rech Med Methodes et kits pour le diagnostic ou le suivi d'une pathologie synoviale ou osteoarticulaire comprenant l'utilisation d'un marqueur specifique de la degradation du tissu synovial
CA2383252A1 (en) 1999-08-24 2001-03-01 Medicure International Inc. Treatment of cardiovascular related pathologies
US6323334B1 (en) 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
AU2001218871A1 (en) 2000-03-21 2001-10-03 Takao Arai Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same
FR2807170B1 (fr) 2000-03-30 2002-06-28 Sipal Charniere elastique a frottement reduit
JP2004506443A (ja) 2000-08-22 2004-03-04 ブライハム　アンド　ウィメンズ　ホスピタル　インコーポレーテッド 心血管状態の診断および処置
WO2002038794A2 (en) 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
US6537221B2 (en) 2000-12-07 2003-03-25 Koninklijke Philips Electronics, N.V. Strain rate analysis in ultrasonic diagnostic images
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US20040253637A1 (en) 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
EP1666881B1 (en) 2001-05-04 2010-02-17 Biosite Incorporated Diagnostic markers of acute coronary syndromes and methods of use thereof
US6905827B2 (en) * 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
WO2003022987A2 (en) * 2001-07-26 2003-03-20 Eos Biotechnology, Inc. Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection
US6810284B1 (en) 2001-11-21 2004-10-26 Pacesetter, Inc. Implantable cardiac stimulation system and method for monitoring diastolic function
PT3072978T (pt) 2002-05-09 2018-10-15 Brigham & Womens Hospital Inc 1l1rl-1 como um marcador de doença cardiovascular
MXPA03004105A (es) * 2002-05-14 2004-10-15 Hoffmann La Roche Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores.
AU2003239544A1 (en) * 2002-05-24 2003-12-12 Tularik Inc. Amplification and overexpression of oncogenes
US8263325B2 (en) * 2002-11-15 2012-09-11 Ottawa Heart Institute Research Corporation Predicting, detecting and monitoring treatment of cardiomyopathies and myocarditis
US20070042978A1 (en) * 2002-12-19 2007-02-22 Jean-Philippe Girard Nf-hev compositions and methods of use
US20040133079A1 (en) * 2003-01-02 2004-07-08 Mazar Scott Thomas System and method for predicting patient health within a patient management system
US20040220155A1 (en) 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
US20060257558A1 (en) 2003-10-31 2006-11-16 Hiroshi Nomura Plasma polymerization of atomically modified surfaces
EP1711622A2 (en) * 2003-11-26 2006-10-18 Applera Corporation Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
WO2005055810A2 (en) 2003-12-05 2005-06-23 The Cleveland Clinic Foundation Risk markers for cardiovascular disease
US20050196817A1 (en) * 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
JP2005291899A (ja) * 2004-03-31 2005-10-20 Akira Matsumori 心疾患の検査法
EP1833766A1 (en) 2004-12-17 2007-09-19 Clearwater Systems Corp. Method and apparatus for treating fluids
EP1849009B1 (en) 2005-01-24 2008-10-29 F. Hoffmann-La Roche AG The use of cardiac hormones for assessing a cardiovascular risk with respect to the administration of anti-inflammatory drugs.
EP1731910A1 (en) 2005-06-07 2006-12-13 F. Hoffmann-La Roche Ag Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases
US20070021977A1 (en) * 2005-07-19 2007-01-25 Witt Biomedical Corporation Automated system for capturing and archiving information to verify medical necessity of performing medical procedure
JP4820192B2 (ja) 2006-03-17 2011-11-24 一般財団法人化学及血清療法研究所 急性冠症候群でのａｄａｍｔｓ１３の測定と利用
ES2646142T3 (es) * 2006-04-24 2017-12-12 Critical Care Diagnostics, Inc. Evaluación de la eficacia de un tratamiento en un sujeto en función de los niveles de ST2
WO2007143295A2 (en) 2006-04-27 2007-12-13 Critical Care Diagnostics, Inc. Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
DK2021796T3 (da) 2006-05-01 2012-05-29 Critical Care Diagnostics Inc Diagnose af hjerte-kar-sygdom
DK2019965T3 (en) 2006-05-02 2015-07-20 Critical Care Diagnostics Inc DIFFERENTIAL BETWEEN LUNG AND Cardiovascular Disease
US8147817B2 (en) * 2006-05-04 2012-04-03 The Brigham And Women's Hospital, Inc. IL-33 in the treatment and diagnosis of diseases and disorders
RU2312591C1 (ru) 2006-06-14 2007-12-20 Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Федерального агентства по здравоохранению и социальному развитию" Способ прогнозирования развития риска внезапной смерти у больных с лево- и правожелудочковой экстрасистолией
US20080233191A1 (en) 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
US20090111708A1 (en) 2007-05-11 2009-04-30 Seddon Johanna M Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk
GB0713404D0 (en) 2007-07-11 2007-08-22 Integra Sp Ipr Ltd Altio graph
US20100267062A1 (en) 2007-09-26 2010-10-21 Norbert Frey Osteopontin as Novel Prognostic Biomarker for Heart Failure
FR2923029B1 (fr) 2007-10-26 2009-11-20 Minima Lunettes de type sans entourage a branches filaires
SI2827152T1 (sl) 2008-04-18 2016-10-28 Critical Care Diagnostics,Inc. Napovedovanje tveganja večjih neželenih srčno-žilnih dogodkov
WO2010054810A1 (en) 2008-11-11 2010-05-20 B.R.A.H.M.S Ag Prognosis and risk assessment in patients suffering from heart failure by determining the level of adm and bnp
BR112012011230A2 (pt) 2009-11-13 2016-04-05 Bg Medicine Inc fatores de risco e previsão de infarto do miocárdio
RU2625014C2 (ru) 2010-04-09 2017-07-11 Критикал Кэа Дайэгностикс, Инк. Антитела против растворимого st-2 человека и способы анализа
RU2618437C2 (ru) 2010-11-01 2017-05-03 Б.Р.А.Х.М.С Гмбх Оценка прогноза и риска пациентов с неспецифическими жалобами
RU2452394C1 (ru) 2010-11-09 2012-06-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Ульяновский государственный университет Способ прогнозирования риска смерти больных хронической сердечной недостаточностью
US8728742B2 (en) 2011-03-17 2014-05-20 Critical Care Diagnostics, Inc. Methods predicting risk of an adverse clinical outcome
JP6134316B2 (ja) 2011-07-18 2017-05-24 クリティカル ケア ダイアグノスティクス インコーポレイテッド 心臓血管疾患を治療する方法および運動療法の有効性を予測する方法
EP3434260A1 (en) 2012-05-18 2019-01-30 Critical Care Diagnostics, Inc. Methods for treating or predicting risk of ventricular tachyarrhythmia event
RU2019107598A (ru) 2012-08-16 2019-03-28 Критикал Кэа Дайэгностикс, Инк. Способы прогнозирования риска развития гипертензии
RU2015110054A (ru) 2012-08-21 2016-10-10 Критикал Кэа Дайэгностикс, Инк. Мультимаркерная стратификация риска
JP6178687B2 (ja) 2013-09-27 2017-08-09 富士機械工業株式会社 グラビア塗工装置
CN106461636A (zh) 2014-01-10 2017-02-22 重症监护诊断股份有限公司 用于测定心力衰竭风险的方法和系统
USD770057S1 (en) 2014-04-14 2016-10-25 Critical Care Diagnostics, Inc. Blood test kit
US9934249B2 (en) 2014-06-03 2018-04-03 Conduent Business Machines Services, Llc Systems and methods for context-aware and personalized access to visualizations of road events
USD800332S1 (en) 2014-09-23 2017-10-17 Critical Care Diagnostics, Inc. Blood test kit
USD800333S1 (en) 2014-09-23 2017-10-17 Critical Care Diagnostics, Inc. Blood test kit
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker

Also Published As

Publication number Publication date
DK2386860T3 (en) 2015-02-09
US20110262941A1 (en) 2011-10-27
EP2241888B1 (en) 2011-10-05
EP2848938A1 (en) 2015-03-18
DK2241888T3 (da) 2012-01-30
ES2529618T3 (es) 2015-02-23
JP2009534691A (ja) 2009-09-24
US11016103B2 (en) 2021-05-25
ES2646142T3 (es) 2017-12-12
JP2012181200A (ja) 2012-09-20
EP2010912B1 (en) 2010-08-04
US20140045200A1 (en) 2014-02-13
US7998683B2 (en) 2011-08-16
JP2016001193A (ja) 2016-01-07
PL2386860T3 (pl) 2015-08-31
EP3255432A1 (en) 2017-12-13
ATE476657T1 (de) 2010-08-15
US9568481B2 (en) 2017-02-14
EP2241888A2 (en) 2010-10-20
EP2848938B1 (en) 2017-08-02
JP5806165B2 (ja) 2015-11-10
US20210255200A1 (en) 2021-08-19
EP2386860A3 (en) 2012-02-22
US8617825B2 (en) 2013-12-31
HK1164443A1 (zh) 2012-09-21
HK1208724A1 (zh) 2016-03-11
US20170131294A1 (en) 2017-05-11
US20120040381A1 (en) 2012-02-16
JP6214604B2 (ja) 2017-10-18
EP2010912A2 (en) 2009-01-07
ES2378314T3 (es) 2012-04-11
PL2386860T4 (pl) 2015-09-30
CA2650201A1 (en) 2007-11-08
ES2351623T3 (es) 2011-02-08
CA2650201C (en) 2020-10-20
AU2007244927A1 (en) 2007-11-08
US20070248981A1 (en) 2007-10-25
AU2007244927B2 (en) 2012-01-12
DE602007008224D1 (de) 2010-09-16
EP2010912A4 (en) 2009-06-10
ATE527544T1 (de) 2011-10-15
EP2386860A2 (en) 2011-11-16
US9057733B2 (en) 2015-06-16
JP5383480B2 (ja) 2014-01-08
PL2848938T3 (pl) 2018-02-28
US20190041403A1 (en) 2019-02-07
EP2241888A3 (en) 2010-11-03
WO2007127749A2 (en) 2007-11-08
EP2386860B1 (en) 2014-11-05
EP3255432B1 (en) 2019-01-23
JP2017215347A (ja) 2017-12-07
WO2007127749A3 (en) 2008-03-20
US10067146B2 (en) 2018-09-04
DK2848938T3 (da) 2017-11-13

Similar Documents

Publication Publication Date Title
HK1248311B (zh) 預測死亡率及檢測重症疾病
Fan et al. Diagnosing sepsis–The role of laboratory medicine
Saukkonen et al. Association of cell-free plasma DNA with hospital mortality and organ dysfunction in intensive care unit patients
Hovatta et al. Leukocyte telomere length in the Finnish diabetes prevention study
JP2009501333A5 (zh)
CN106574294A (zh) 用于通过定量pcr从人粪便样本诊断结肠直肠癌的方法、引物及试剂盒
GB0510943D0 (en) Improved immunoassay methods
WO2006026020A3 (en) Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin
NO20083820L (no) Deteksjon av kreft ved forhoyede nivaer av BCL-2
SG179122A1 (en) Serum-based biomarkers of pancreatic cancer and uses thereof for disease detection and diagnosis
CA2623653A1 (en) Use of n-myristoyltransferase on non-tumor tissue for cancer diagnosis
WO2011021041A3 (en) Survival prognostic assay
DE602005022709D1 (de) Quantifizierungsverfahren für die vegf isoformen einer biologischen probe
de Almeida et al. Estimating the concentration of urea and creatinine in the human serum of normal and dialysis patients through Raman spectroscopy
EP1898215A4 (en) METHOD FOR ANALYZING ENDOCRINE SUBSTANCE IN A SPECIMEN
WO2009014987A3 (en) Identification and quantification of biomarkers for evaluating the risk of preterm birth
Garcia de Guadiana-Romualdo et al. Prognostic performance of pancreatic stone protein in critically ill patients with sepsis
Ge et al. Monitoring of intestinal inflammation and prediction of recurrence in ulcerative colitis
Lin et al. Assessment of measurement of salivary urea by ATR-FTIR spectroscopy to screen for CKD
JP2011523037A5 (zh)
KR102281793B1 (ko) 혈중 메타볼리즘을 이용한 건강 상태 정보 제공 장치 및 그 방법
Lee et al. Clinical use of targeted high-throughput whole-genome sequencing for a dengue virus variant
Siew et al. Acute kidney injury: a not-so-silent disease
CN203616318U (zh) 一种急性心梗的风险评估组合检测卡
Baxter et al. DNA from fecal immunochemical test can replace stool for microbiota-based colorectal cancer screening

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230420